180 related articles for article (PubMed ID: 20026900)
1. Analysis of HIF-1a and its regulator, PHD2, in retroperitoneal sarcomas: clinico-pathologic implications.
Huang JH; Lee FS; Pasha TL; Sammel MD; Karakousis G; Xu G; Fraker D; Zhang PJ
Cancer Biol Ther; 2010 Feb; 9(4):303-11. PubMed ID: 20026900
[TBL] [Abstract][Full Text] [Related]
2. miR-21 contributes to renal protection by targeting prolyl hydroxylase domain protein 2 in delayed ischaemic preconditioning.
Jiao X; Xu X; Fang Y; Zhang H; Liang M; Teng J; Ding X
Nephrology (Carlton); 2017 May; 22(5):366-373. PubMed ID: 27030384
[TBL] [Abstract][Full Text] [Related]
3. Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and prolyl hydroxylase domain protein 2 in cutaneous squamous cell carcinoma and precursor lesions and their relationship with histological stages and clinical features.
An X; Xu G; Yang L; Wang Y; Li Y; McHepange UO; Shen G; Tu Y; Tao J
J Dermatol; 2014 Jan; 41(1):76-83. PubMed ID: 24354513
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Endothelial PHD2 Suppresses Post-Ischemic Kidney Inflammation through Hypoxia-Inducible Factor-1.
Rajendran G; Schonfeld MP; Tiwari R; Huang S; Torosyan R; Fields T; Park J; Susztak K; Kapitsinou PP
J Am Soc Nephrol; 2020 Mar; 31(3):501-516. PubMed ID: 31996410
[TBL] [Abstract][Full Text] [Related]
5. The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
Fox SB; Generali D; Berruti A; Brizzi MP; Campo L; Bonardi S; Bersiga A; Allevi G; Milani M; Aguggini S; Mele T; Dogliotti L; Bottini A; Harris AL
Breast Cancer Res; 2011 Feb; 13(1):R16. PubMed ID: 21291529
[TBL] [Abstract][Full Text] [Related]
6. Gene Transfer of Prolyl Hydroxylase Domain 2 Inhibits Hypoxia-inducible Angiogenesis in a Model of Choroidal Neovascularization.
Takei A; Ekström M; Mammadzada P; Aronsson M; Yu M; Kvanta A; André H
Sci Rep; 2017 Feb; 7():42546. PubMed ID: 28186209
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-Inducible Factor 2a Expression Is Positively Correlated With Gleason Score in Prostate Cancer.
Pavlakis D; Kampantais S; Gkagkalidis K; Gourvas V; Memmos D; Tsionga A; Dimitriadis G; Vakalopoulos I
Technol Cancer Res Treat; 2021; 20():1533033821990010. PubMed ID: 33752529
[TBL] [Abstract][Full Text] [Related]
8. Silencing of HIF prolyl-hydroxylase 2 gene in the renal medulla attenuates salt-sensitive hypertension in Dahl S rats.
Zhu Q; Hu J; Han WQ; Zhang F; Li PL; Wang Z; Li N
Am J Hypertens; 2014 Jan; 27(1):107-13. PubMed ID: 24190904
[TBL] [Abstract][Full Text] [Related]
9. Identification of Small-Molecule PHD2 Zinc Finger Inhibitors that Activate Hypoxia Inducible Factor.
Arsenault PR; Song D; Bergkamp M; Ravaschiere AM; Navalsky BE; Lieberman PM; Lee FS
Chembiochem; 2016 Dec; 17(24):2316-2323. PubMed ID: 27770548
[TBL] [Abstract][Full Text] [Related]
10. Prolyl hydroxylase domain 2 deficiency promotes skeletal muscle fiber-type transition via a calcineurin/NFATc1-dependent pathway.
Shin J; Nunomiya A; Kitajima Y; Dan T; Miyata T; Nagatomi R
Skelet Muscle; 2016; 6():5. PubMed ID: 26949511
[TBL] [Abstract][Full Text] [Related]
11. Intermediary metabolite precursor dimethyl-2-ketoglutarate stabilizes hypoxia-inducible factor-1α by inhibiting prolyl-4-hydroxylase PHD2.
Hou P; Kuo CY; Cheng CT; Liou JP; Ann DK; Chen Q
PLoS One; 2014; 9(11):e113865. PubMed ID: 25420025
[TBL] [Abstract][Full Text] [Related]
12. Defective Tibetan PHD2 binding to p23 links high altitude adaption to altered oxygen sensing.
Song D; Li LS; Arsenault PR; Tan Q; Bigham AW; Heaton-Johnson KJ; Master SR; Lee FS
J Biol Chem; 2014 May; 289(21):14656-65. PubMed ID: 24711448
[TBL] [Abstract][Full Text] [Related]
13. Regulation of ventilatory sensitivity and carotid body proliferation in hypoxia by the PHD2/HIF-2 pathway.
Hodson EJ; Nicholls LG; Turner PJ; Llyr R; Fielding JW; Douglas G; Ratnayaka I; Robbins PA; Pugh CW; Buckler KJ; Ratcliffe PJ; Bishop T
J Physiol; 2016 Mar; 594(5):1179-95. PubMed ID: 26337139
[TBL] [Abstract][Full Text] [Related]
14. Significance of prolyl hydroxylase 2 in the interference of aryl hydrocarbon receptor and hypoxia-inducible factor-1 alpha signaling.
Seifert A; Katschinski DM; Tonack S; Fischer B; Navarrete Santos A
Chem Res Toxicol; 2008 Feb; 21(2):341-8. PubMed ID: 18072750
[TBL] [Abstract][Full Text] [Related]
15. The Endothelial Prolyl-4-Hydroxylase Domain 2/Hypoxia-Inducible Factor 2 Axis Regulates Pulmonary Artery Pressure in Mice.
Kapitsinou PP; Rajendran G; Astleford L; Michael M; Schonfeld MP; Fields T; Shay S; French JL; West J; Haase VH
Mol Cell Biol; 2016 May; 36(10):1584-94. PubMed ID: 26976644
[TBL] [Abstract][Full Text] [Related]
16. Overexpression and nuclear translocation of hypoxia-inducible factor prolyl hydroxylase PHD2 in head and neck squamous cell carcinoma is associated with tumor aggressiveness.
Jokilehto T; Rantanen K; Luukkaa M; Heikkinen P; Grenman R; Minn H; Kronqvist P; Jaakkola PM
Clin Cancer Res; 2006 Feb; 12(4):1080-7. PubMed ID: 16489060
[TBL] [Abstract][Full Text] [Related]
17. The ribosomal chaperone NACA recruits PHD2 to cotranslationally modify HIF-α.
Song D; Peng K; Palmer BE; Lee FS
EMBO J; 2022 Nov; 41(22):e112059. PubMed ID: 36219563
[TBL] [Abstract][Full Text] [Related]
18. Gambogic acid inhibits angiogenesis through inhibiting PHD2-VHL-HIF-1α pathway.
Lu N; Hui H; Yang H; Zhao K; Chen Y; You QD; Guo QL
Eur J Pharm Sci; 2013 May; 49(2):220-6. PubMed ID: 23501055
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of angiogenesis through stabilization of hypoxia-inducible factor-1 by silencing prolyl hydroxylase domain-2 gene.
Wu S; Nishiyama N; Kano MR; Morishita Y; Miyazono K; Itaka K; Chung UI; Kataoka K
Mol Ther; 2008 Jul; 16(7):1227-34. PubMed ID: 18500250
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer.
Boddy JL; Fox SB; Han C; Campo L; Turley H; Kanga S; Malone PR; Harris AL
Clin Cancer Res; 2005 Nov; 11(21):7658-63. PubMed ID: 16278385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
